US Stem Cell Inc (OTCMKTS: USRM) has enjoyed a prosperous 2017 as a whole so far, when you back up and look at the whole picture. This, a stock that was trading as low as .0019/share starting out in January, went on to fall just a hair shy of the six cent mark, at .0599. That was a run of more than 3,000% and it happened in two main thrusts within the first two months of the calendar year.
Each of those intense surges was followed by a period of sideways and consolidative trading, but each time, they have given way to further moves to the upside. Most recently, the stock came down to below the two-cent area, and has since run back over a nickel on the strength of some encouraging financials, including the first time in the company’s history that it recorded a positive cash flow.
But is a solid financial filing worthy of the monumental increases that shares of US Stem Cell Inc (OTCMKTS: USRM) have seen in 2017? The company certainly didn’t post 3,000% increases in any statistical category, so what gives? Why has the market dictated USRM surge so high in price this year?
The answer could lie in the extreme high potential of the market space in which the company operates. According to the world-renowned Mayo Clinic, regenerative medicine is a game-changing area of medicine with the potential to fully heal damaged tissues and organs, offering solutions and hope for people who have conditions that today are beyond repair. Regenerative medicine itself isn’t new, but advances in developmental and cell biology, immunology, and other fields have unlocked new opportunities. According to some estimates, the global market valuation of the regenerative medicine/cell therapy industry could exceed $100B annually within the next five years.
USRM is working hard to make its mark on the regenerative medicine / cellular therapy industry by marketing cell based therapeutics that prevent, treat, or cure disease by repairing and replacing damaged or aged tissue, cells, and organs and restoring their normal function. The company holds the believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, and ultimately lessen patient burdens and reducing the economic impact disease imposes upon society.
Its business includes three divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic), the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.
It is perhaps the extreme high potential of a USRM, and its operating space that leads many investors to see the hidden value in this company. The regenerative medicine business has some enormous players that already have a hold over the traditional medicine markets. That paints a target on smaller companies that are working diligently to develop viable regenerative treatments for a wide array of degenerative diseases. It would only take one key breakthrough to make USRM the subject of a buyout.
Perhaps the investment community senses this, and that may explain, at least partially, the meteoric rise of US Stem Cell Inc (OTCMKTS: USRM) in 2017. We’re definitely going to want to keep a very close eye on any and all developments coming out of the USRM camp. We’ll be certain to relay any significant changes along to our readers. Stay up to date on USRM by signing up for our 100% free penny stock newsletter. It takes just a second to submit your email into the box below, so subscribe now!